MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/bju.70303

Медицинская библиотека · BJU international · 2026

Multiparametric MRI in prostate cancer active surveillance: results from the Miami Active Surveillance Trial (MAST) trial.

Sharifi Seyed Hossein Hosseini, Williams Adam, Ryan Jonathan T, Ajami Tarek, Nativ Omri Falik, Han Sunwoo, Reis Isildinha M, Soodana-Prakash Nachiketh, Khandekar Archan, Swain Sanjaya, Kryvenko Oleksandr N, Stoyanova Radka, Pollack Alan, Castillo Patricia R, Nahar Bruno, Ritch Chad R, Kava Bruce, Gonzalgo Mark L, Parekh Dipen J, Punnen Sanoj

СтатьяПеревод в очереди

Аннотация

OBJECTIVES

To examine the role of multiparametric magnetic resonance imaging (mpMRI) in enhancing prostate cancer (PCa) detection and selecting candidates for active surveillance (AS), given that its utility in monitoring disease progression remains unclear.

PATIENTS AND

METHODS

The Miami Active Surveillance Trial (MAST) is a prospective trial of men undergoing serial mpMRI and biopsies on AS for PCa. Participants had annual mpMRI with MRI-targeted and systematic biopsies at confirmatory (12-18 months) and subsequent intervals (12, 24, and 36 months). Grade progression was defined as an upgrade from Grade Group (GG) 1 to GG ≥2 or GG 2 to GG ≥3. The performance of MRI was evaluated at baseline (prior to confirmatory biopsy) and on subsequent biopsies for association with grade progression. Fine and Gray competing-risk models evaluated MRI for predicting grade progression after controlling for risk factors.

RESULTS

Among 205 men, 79 (38.5%) had grade progression at the conclusion of the trial (36 months), with 40 (19.5%) men having grade progression at confirmatory biopsy, and the remaining 39 (2.0-9.8%/year) progressing on subsequent biopsies. A Prostate Imaging-Reporting And Data System (PI-RADS) score of 4 or 5 (vs no suspicious lesions or PI-RADS 1 and 2) on baseline MRI (prior to confirmatory biopsy) was an independent predictor of grade progression on confirmatory biopsy (Gray's test P < 0.001), with volume progression treated as a competing risk. At 36 months, MRI-only surveillance would have avoided 45% of biopsies but missed 32% of progression events.

CONCLUSION

Pre-confirmatory biopsy MRI independently predicted grade progression on confirmatory and subsequent biopsies during AS; however, false positives and negatives still occur highlighting the need for periodic biopsy of the prostate.

Для цитирования: Sharifi Seyed Hossein Hosseini, Williams Adam, Ryan Jonathan T, Ajami Tarek, Nativ Omri Falik, Han Sunwoo, Reis Isildinha M, Soodana-Prakash Nachiketh, Khandekar Archan, Swain Sanjaya, Kryvenko Oleksandr N, Stoyanova Radka, Pollack Alan, Castillo Patricia R, Nahar Bruno, Ritch Chad R, Kava Bruce, Gonzalgo Mark L, Parekh Dipen J, Punnen Sanoj. Multiparametric MRI in prostate cancer active surveillance: results from the Miami Active Surveillance Trial (MAST) trial.. BJU international. 2026. DOI: 10.1111/bju.70303.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.